The Oncology Brothers—Rahul Gosain, MD, of the University of Rochester, and Rohit Gosain, MD, of the UPMC Hillman Cancer Center—were live at ASCO 2023 to discuss findings from the TROPiCS-02 study with Aditya Bardia, MD, of Massachusetts General Hospital at Harvard Medical School. Dr. Bardia discussed the Trop-2-directed antibody-drug conjugate sacituzumab govitecan, which is approved by the US Food and Drug Administration for patients with metastatic triple-negative breast cancer in the first-line and later setting, as well as patients with metastatic hormone receptor-positive (HR+) breast cancer who have received at least 2 prior lines of systemic therapy.
“Overall survival (OS) is the most important endpoint for any patient, for any provider,” said Dr. Bardia. “We see that there is an improvement in OS that is maintained with sacituzumab govitecan compared to standard chemotherapy.”
The phase 3 TROPiCS-02 study showed a progression-free survival (PFS) and overall survival (OS) benefit with sacituzumab govitecan in patients with HR+/human epidermal growth factor receptor 2-negative (HER2‒) metastatic breast cancer.
The study included an mRNA analytical cohort of 197 patients with HR+/HER2‒ metastatic breast cancer, 49% of whom had TACSTD2 high expression, and 51% had TACSTD2 low expression. All patients had received at least 1 prior taxane, endocrine therapy, and a CDK4/6 inhibitor, as well as 2 to 4 prior chemotherapy regimens for metastatic breast cancer.
Sacituzumab govitecan demonstrated a numerically higher median PFS versus treatment of physician’s choice regardless of TACSTD2 expression. OS outcomes also favored sacituzumab govitecan over treatment of physician’s choice regardless of TACSTD2 expression.